TDP1 and cancer: In addition to their use in the clinic to kill cancer cells, alkylation damage is almost unavoidable and it is intriguing to speculate that the progressive accumulation of AP/3′-dRP lesions may also contribute to neurological decline observed in TDP1-deficient patients with spinocerebellar ataxia with axonal neuropathy (SCAN1) (41).